Experimental verification of clinical dose and LET maps for LET-informed proton therapy
Related Experiment Video
Updated: Nov 8, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Mads Lykke Jensen1, Michelle Van Heerden2, Liliana Stolarczyk3
1Department of Radiation Safety and Security, Paul Scherrer Institut PSI, Forschungsstrasse 111, OFLD/005, Villigen, Villigen, 5232, Switzerland.
Abstract:
Objective:Linear energy transfer (LET)-informed proton therapy has the potential to improve biological treatment planning beyond the conventional, constant-RBE assumption. Its clinical translation, however, requires experimental tools capable of verifying spatially resolved dose and dose-averaged LET (LETD) distributions under clinically relevant conditions. We recently introduced an optically stimulated luminescence (OSL) film-based detector system that simultaneously measures two-dimensional (2D) absorbed dose and LETD. This work provides a first assessment of the system for verifying dose and LETDdistributions from clinical proton therapy plans. Approach:The system was tested at two proton therapy centers, ranging from simple uniform fields to more complex geometries, including Bragg curve measurements and a clinically realistic anthropomorphic head phantom treatment plan. Measured dose and LETDdistributions were compared against commercial treatment planning system (TPS) calculations and, for selected fields, to external Monte Carlo particle transport simulations due to the absence of traceability of LETD. For non-uniform irradiations, agreement was assessed using gamma analysis with 3%/2 mm and 5%/2 mm criteria for dose and LETD, respectively. Main results:For uniform fields, measured dose and LETDdistributions generally agreed with TPS and independent Monte Carlo simulations across a range of clinically relevant irradiation conditions. In the Bragg curve measurement, gamma pass rates were 96.6% for dose and 99.7% for LETD, with the largest dose discrepancy observed near the Bragg peak, consistent with a current over-correction of detector quenching in high-LET regions to be improved in future work. In the anthropomorphic phantom, gamma pass rates ranged from 75% to 100% for dose and from 45% to 95% for LETD, with a single layer showing a sub-50% pass rate for LETD. Failing regions were confined to high-dose superior layers for dose and distal-edge, high-LET regions for LETD. Significance:The presented results support the detector system's use as an experimental benchmarking tool for TPS-calculated dose and LETDmaps. Given this and the system's ability to simultaneously measure 2D dose and LETDmaps with high spatial resolution and minimal field perturbation, the system shows promise for future commissioning workflows for LET-informed proton therapy.
More Related Videos
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021